Literature DB >> 34120230

Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer.

Koichiro Kimura1, Soichiro Yoshida2, Junichi Tsuchiya1, Ichiro Yamada1, Hajime Tanaka3, Minato Yokoyama3, Yoh Matsuoka3, Ryoichi Yoshimura4, Ukihide Tateishi1, Yasuhisa Fujii3.   

Abstract

OBJECTIVES: To examine the usefulness of the texture analysis (TA) of apparent diffusion coefficient (ADC) maps in predicting the chemoradiotherapy (CRT) response of muscle-invasive bladder cancer (MIBC).
METHODS: We reviewed 45 MIBC patients who underwent cystectomy after CRT. CRT response was assessed through histologic evaluation of cystectomy specimens. Two radiologists determined the volume of interest for the index lesions on ADC maps of pretherapeutic 1.5-T MRI and performed TA using the LIFEx software. Forty-six texture features (TFs) were selected based on their contribution to the prediction of CRT sensitivity. To evaluate diagnostic performance, diagnostic models from the selected TFs were created using random forest (RF) and support vector machine (SVM), respectively.
RESULTS: Twenty-three patients achieved pathologic complete response (pCR) to CRT. The feature selection identified first quartile ADC (Q1 ADC), gray-level co-occurrence matrix (GLCM) correlation, and GLCM homogeneity as important in predicting CRT response. Patients who achieved pCR showed significantly lower Q1 ADC and GLCM correlation values (0.66 × 10-3 mm2/s and 0.53, respectively) than those who did not (0.81 × 10-3 mm2/s and 0.70, respectively; p < 0.05 for both). The AUCs of the RF and SVM models incorporating the selected TFs were 0.82 (95% confidence interval [CI]: 0.67-0.97) and 0.96 (95% CI: 0.91-1.00), respectively, and the AUC of the SVM model was better than that of the mean ADC value (0.76, 95% CI: 0.61-0.90; p = 0.0037).
CONCLUSION: TFs can serve as imaging biomarkers in MIBC patients for predicting CRT sensitivity. TAs of ADC maps can potentially optimize patient selection for CRT. KEY POINTS: • Texture analysis of ADC maps and feature selection identified important texture features for classifying pathologic tumor response in patients with muscle-invasive bladder cancer. • The machine learning model incorporating the texture features set, which included first quartile ADC, GLCM correlation, and GLCM homogeneity, showed high performance in predicting chemoradiotherapy response. • Texture features could serve as imaging biomarkers that optimize eligible patient selection for chemoradiotherapy in muscle-invasive bladder cancer.
© 2021. European Society of Radiology.

Entities:  

Keywords:  Chemoradiotherapy; Diffusion magnetic resonance imaging; Machine learning; Urinary bladder neoplasms

Mesh:

Year:  2021        PMID: 34120230     DOI: 10.1007/s00330-021-08110-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  4 in total

Review 1.  Advances in Diagnosis and Therapy for Bladder Cancer.

Authors:  Xinzi Hu; Guangzhi Li; Song Wu
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

2.  Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Authors:  Yusuke Uchida; Soichiro Yoshida; Yuki Arita; Hiroki Shimoda; Koichiro Kimura; Ichiro Yamada; Hajime Tanaka; Minato Yokoyama; Yoh Matsuoka; Masahiro Jinzaki; Yasuhisa Fujii
Journal:  Diagnostics (Basel)       Date:  2022-03-26

3.  Breast Cancer Classification on Multiparametric MRI - Increased Performance of Boosting Ensemble Methods.

Authors:  Alexandros Vamvakas; Dimitra Tsivaka; Andreas Logothetis; Katerina Vassiou; Ioannis Tsougos
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods.

Authors:  Xuejiao Han; Jing Yang; Jingwen Luo; Pengan Chen; Zilong Zhang; Aqu Alu; Yinan Xiao; Xuelei Ma
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.